Havana, Jan 13.- The Engelhardt Institute of Molecular Biology (EIMB), of the Russian Academy of Sciences (RAS), and the Immunoassay Center of the Group of Cuban biotechnology and pharmaceutical industries, Biocubafarma, signed this Sunday a cooperation agreement for scientific research.
This agreement is focused on obtaining products that are priorities for the public health of both countries, according to information that appears on Biocubafarma's Facebook profile.
The source highlights that the agreement will also allow the institutional development processes of the Immunoassay Center of the Group of the biotechnology and pharmaceutical industries of Cuba to be promoted.
Biocubafarma is a business group founded on November 27, 2012 by the Council of Ministers of Cuba with the objective of producing high-tech medicines, equipment and services aimed at improving the health of the Cuban people and the generation of exportable goods and services. as a result of the scientific and technical development achieved by the Caribbean island. (Text and Photo. Cubasí)